Novo Nordisk cuts money prices for Wegovy, Ozempic

Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight reduction drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the corporate and the Trump administration to make the treatments more accessible. 

The Danish drugmaker is lowering the worth of the drugs for existing cash-paying patients to $349 per thirty days from $499 per thirty days. But Novo Nordisk said the cash-pay cost of the best dose of Ozempic will remain $499 per thirty days. 

Also on Monday, Novo Nordisk launched a brief introductory offer, which can allow latest cash-paying patients to access the 2 lowest doses of Wegovy and Ozempic for $199 per thirty days for the primary two months of treatment. After that period, people move to the brand new standard monthly direct-to-consumer price. The corporate’s introductory offer ends on March 31. 

The announcements come days after President Donald Trump struck deals with Novo Nordisk and chief rival Eli Lilly to make their popular GLP-1 drugs easier for Americans to access and afford. Those agreements will involve cutting the costs the federal government pays for the drugs, introducing Medicare coverage of obesity drugs for the primary time for certain patients and offering discounted medicines on the federal government’s latest direct-to-consumer website launching in January called TrumpRx. 

“Our latest savings offers provide immediate impact, bringing forward greater cost savings for many who are currently without coverage or decide to self-pay,” said Dave Moore, Novo Nordisk’s head of U.S. operations, said in a release. “It is an element of a bigger technique to expand access that features constructing relationships with telehealth providers and major retailers, expanding coverage, and dealing with the Administration to lower costs for people living with chronic diseases like obesity.”

The Trump administration said starting doses of existing injections like Wegovy and Eli Lilly’s weight reduction drug Zepbound will probably be $350 per thirty days on TrumpRx, but will “trend down” to $245 per thirty days over a two-year period. 

On the day the deals were announced, Eli Lilly said it would lower prices by $50 by itself direct-to-consumer platform, LillyDirect, which already offers Zepbound at a reduction to cash-paying patients. The multidose pen of Zepbound will probably be available at $299 per thirty days at the bottom dose, with additional doses being priced as much as $449 per thirty days.

Novo Nordisk’s latest cash-pay offers can be found through Wegovy.com or Ozempic.com, the corporate’s direct-to-consumer pharmacy, NovoCare, and other participating organizations and telehealth providers that work directly with the drugmaker, including Costco, GoodRx, WeightWatchers, Ro, LifeMD and eMed.